<!--

File produced by pipelineRunner package (for JATS 2 SCJATS with pipeline SCJATS)
At: 2025-04-06T19:48:50.238Z

Version        : 1.16.1
Last update    : 2024-08-27
Modified by    : dunnm

-->
<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="letter"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Sex Med</journal-id><journal-id journal-id-type="iso-abbrev">Sex Med</journal-id><journal-id journal-id-type="publisher-id">smoa</journal-id><journal-title-group><journal-title>Sexual Medicine</journal-title></journal-title-group><issn pub-type="epub">2050-1161</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40191611</article-id><article-id pub-id-type="pmc">PMC11972624</article-id><article-id pub-id-type="doi">10.1093/sexmed/qfaf020</article-id><article-id pub-id-type="publisher-id">qfaf020</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00010</subject></subj-group></article-categories><title-group><article-title>Letter to the Editor on &#x0201c;Association of total testosterone levels with cardiometabolic diseases in men with erectile dysfunction&#x0201d;</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Selinger</surname><given-names>Scott</given-names></name><degrees>MD, FACP</degrees><!--scott.selinger@austin.utexas.edu--><aff>
<institution>Department of Internal Medicine</institution>, University of Texas at Austin Dell Medical School, Austin, TX 78712, <country country="US">United States</country></aff><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name><surname>Thoreson</surname><given-names>Gregory R</given-names></name><degrees>MD, FACS</degrees><aff>
<institution>Department of Surgery and Perioperative Care, University of Texas at Austin Dell Medical School</institution>, Austin, TX 78712, <country country="US">United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1">Corresponding author: Department of Internal Medicine, University of Texas at Austin Dell Medical School, Austin, TX 78712, United States. Email: <email>scott.selinger@austin.utexas.edu</email></corresp></author-notes><pub-date pub-type="collection"><month>4</month><year>2025</year></pub-date><pub-date pub-type="epub" iso-8601-date="2025-04-06"><day>06</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>06</day><month>4</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>qfaf020</elocation-id><history><date date-type="received"><day>03</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>09</day><month>3</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025. Published by Oxford University Press on behalf of The International Society for Sexual Medicine.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="qfaf020.pdf"/><counts><page-count count="1"/></counts></article-meta></front><body><p>We appreciate the work of Chen et&#x000a0;al.<xref rid="ref1" ref-type="bibr"><sup>1</sup></xref> in furthering the linkage between low testosterone and a myriad of comorbidities with increased cardiovascular disease. There are several clarifying points on their work we would like to add.</p><p>First, this information should serve to remind the medical and general community that there is little to no link between total testosterone and erectile dysfunction (ED), as ED severity was similar between men with low and normal testosterone and only a third of men presenting with ED had low testosterone. The lack of free testosterone levels is unfortunate, as it has been postulated that the symptom burden and disease risk correlate better with free than total levels.<xref rid="ref2" ref-type="bibr"><sup>2</sup></xref> The inverse correlation of total testosterone and body mass index (BMI) is notable as BMI is inversely correlated with serum hormone binding globulin (SHBG), leading to higher free testosterone levels, while age is more directly associated with SHBG levels.<xref rid="ref3" ref-type="bibr"><sup>3</sup></xref></p><p>Low testosterone can signal global cardiometabolic disease, as Chen noted nearly 40% increased incidence of diabetes, hypertension and dyslipidemia in the low testosterone group (though interestingly the average HbA1c was nearly the same, suggesting substantially worse diabetes control in the hypogonadal group). However, testosterone supplementation has no major effect on disease outcomes for these conditions including glycemic remission<xref rid="ref4" ref-type="bibr"><sup>4</sup></xref> or cardiovascular disease outcomes.<xref rid="ref5" ref-type="bibr"><sup>5</sup></xref> It may be that while testosterone is a marker for chronic disease and comorbidity, in the same vein as sodium, hemoglobin and vitamin D, it is not an effective target to reduce illness burden.</p><p>The strongest argument to be made by this longitudinal study is the potential for high impact interventions or touchpoints for men with multimorbidity presenting to urology clinics for erectile dysfunction. Long-heralded as the &#x0201c;canary in the coal mine&#x0201d; for cardiovascular disease, given the progressive and relative dearth of high quality accessible primary care combined with masculinity-associated dearth of timely healthcare-seeking behavior in men, those asking for help with ED have already opened the door to a discussion around lifestyle-based interventions to improve comorbid conditions and we as their trusted providers should make a point to walk through that door together.</p></body><back><ack id="qfaf020-ack"><title>Acknowledgments</title><p>None declared.</p></ack><sec id="sec1"><title>Funding</title><p>None declared.</p></sec><sec sec-type="COI-statement" id="sec2"><title>Conflicts of interest</title><p>None declared.</p></sec><ref-list id="bib1"><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Chen</surname> &#x000a0;<given-names>BT</given-names></string-name>, <string-name><surname>Tsai</surname> &#x000a0;<given-names>PJ</given-names></string-name>, <string-name><surname>Jiann</surname> &#x000a0;<given-names>BP</given-names></string-name></person-group>. <article-title>Association of total testosterone levels with cardiometabolic diseases in men with erectile dysfunction</article-title>. <source>Sex Med</source>. <year>2025</year>;<volume>12</volume>(<issue>6</issue>). <pub-id pub-id-type="doi">10.1093/sexmed/qfae089</pub-id></mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Antonio</surname> &#x000a0;<given-names>L</given-names></string-name>, <string-name><surname>Wu</surname> &#x000a0;<given-names>FC</given-names></string-name>, <string-name><surname>O'Neill</surname> &#x000a0;<given-names>TW</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Low free testosterone is associated with Hypogonadal signs and symptoms in men with normal Total testosterone</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2016</year>;<volume>101</volume>(<issue>7</issue>):<fpage>2647</fpage>&#x02013;<lpage>2657</lpage>. <pub-id pub-id-type="doi">10.1210/jc.2015-4106</pub-id><pub-id pub-id-type="pmid">26909800</pub-id>
</mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Cooper</surname> &#x000a0;<given-names>LA</given-names></string-name>, <string-name><surname>Page</surname> &#x000a0;<given-names>ST</given-names></string-name>, <string-name><surname>Amory</surname> &#x000a0;<given-names>JK</given-names></string-name>, <string-name><surname>Anawalt</surname> &#x000a0;<given-names>BD</given-names></string-name>, <string-name><surname>Matsumoto</surname> &#x000a0;<given-names>AM</given-names></string-name></person-group>. <article-title>The association of obesity with sex hormone-binding globulin is stronger than the association with ageing--implications for the interpretation of total testosterone measurements</article-title>. <source>Clin Endocrinol</source>. <year>2015</year>;<volume>83</volume>(<issue>6</issue>):<fpage>828</fpage>&#x02013;<lpage>833</lpage>. <pub-id pub-id-type="doi">10.1111/cen.12768</pub-id></mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Bhasin</surname> &#x000a0;<given-names>S</given-names></string-name>, <string-name><surname>Lincoff</surname> &#x000a0;<given-names>AM</given-names></string-name>, <string-name><surname>Nissen</surname> &#x000a0;<given-names>SE</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>Effect of testosterone on progression from prediabetes to diabetes in men with hypogonadism: a substudy of the TRAVERSE randomized clinical trial</article-title>. <source>JAMA Intern Med</source>. <year>2024</year>;<volume>184</volume>(<issue>4</issue>):<fpage>353</fpage>&#x02013;<lpage>362</lpage>. <pub-id pub-id-type="doi">10.1001/jamainternmed.2023.7862</pub-id><pub-id pub-id-type="pmid">38315466</pub-id>
</mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name>
<surname>Lincoff</surname> &#x000a0;<given-names>AM</given-names></string-name>, <string-name><surname>Bhasin</surname> &#x000a0;<given-names>S</given-names></string-name>, <string-name><surname>Flevaris</surname> &#x000a0;<given-names>P</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group> &#x000a0;<article-title>TRAVERSE study investigators. Cardiovascular safety of testosterone-replacement therapy</article-title>. <source>N Engl J Med</source>. <year>2023</year>;<volume>389</volume>(<issue>2</issue>):<fpage>107</fpage>&#x02013;<lpage>117</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2215025</pub-id><pub-id pub-id-type="pmid">37326322</pub-id>
</mixed-citation></ref></ref-list></back></article>